A Real World Study of Bamlanivimab in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)

COVID-19 Clinical Trial

— BLAZE-5  

Official title:

A Prospective Cohort Study to Evaluate the Real-world Effectiveness of Bamlanivimab in Participants With Mild-to-moderate COVID-19 at High Risk for Progressing to Severe Illness, With Matched Controls

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04701658
• Other study ID #: 18216
• Secondary ID: J2X-MC-PYAJ
• Status: Completed
• Phase: Phase 2
• Start date: February 1, 2021
• Est. completion date: June 22, 2021

Study information

• Verified date: November 2021
• Source: Eli Lilly and Company
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to find out whether bamlanivimab is able to stop COVID-19 from getting worse. Participants with mild-to-moderate COVID-19 will receive bamlanivimab via an injection into a vein. These participants will be matched to similar COVID-19 patients who received other treatment at a local medical center. All participants will be followed to learn how their disease responds. Participation could last about 3 months and includes two required visits to the study site, with the remainder of assessments performed by phone or by medical record review.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 109
• Est. completion date: June 22, 2021
• Est. primary completion date: June 22, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Years and older

Eligibility

Inclusion Criteria:

• Are currently not hospitalized.

• Have one or more mild or moderate COVID-19 symptoms.

• Must have first positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral infection determination and as soon as possible within 10 days of symptom onset

• Are males or non-breastfeeding females.

• Contraceptive use by males or females should be consistent with local regulations for those participating in clinical studies.

• Are at high risk for progressing to severe COVID-19 and/or hospitalization.

Exclusion Criteria:

• Participants who:

• are hospitalized due to COVID-19, OR

• require oxygen therapy due to COVID-19, OR

• require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity.

• Have peripheral capillary oxygen saturation (SpO2) less than or equal to (=) 90 percent on room air or arterial partial pressure of oxygen/fraction of inspired oxygen (PaO2/FiO2) less than (<) 300, respiratory rate greater than or equal to (=) 30 per minute, heart rate =125 per minute.

• Have body weight <40 kilograms.

• Require mechanical ventilation or anticipated impending need for mechanical ventilation.

• Have known allergies to any of the components used in the formulation of the interventions.

• Suspected or proven serious, active bacterial, fungal, viral, or other infection (besides COVID-19) that in the opinion of the investigator could constitute a risk when taking intervention.

• Have any comorbidity requiring surgery within <7 days, or that is considered life-threatening within 29 days.

• Have any serious concomitant systemic disease, condition, or disorder that, in the opinion of the investigator, should preclude participation in this study.

• Have a history of a positive SARS-CoV-2 serology test.

• Have a history of a positive SARS-CoV-2 test prior to the one serving as eligibility for this study.

• Have received an investigational intervention for SARS-CoV-2 prophylaxis within 30 days before dosing.

• Have received treatment with a SARS-CoV-2-specific monoclonal antibody, remdesivir, or other treatment for COVID-19.

• Have received convalescent COVID-19 plasma treatment.

• Have participated in a previous SARS-CoV-2 vaccine study.

• Have participated, within the last 30 days, in a clinical study involving an investigational intervention. If the previous investigational intervention has a long half-life, 5 half-lives or 30 days, whichever is longer, should have passed.

• Are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.

• Are breast-feeding.

Related Conditions & MeSH terms

• COVID-19

Intervention

Drug:
• Bamlanivimab
Administered intravenously.

Locations

Country	Name	City	State
United States	Presbyterian Medical Center	Albuquerque	New Mexico

Sponsors (2)

Lead Sponsor	Collaborator
Eli Lilly and Company	AbCellera Biologics Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants Who Experience COVID-19 Related Hospitalization or Death From Any Cause	Percentage of Participants who Experience COVID-19 Related Hospitalization or Death From Any Cause. Hospitalization is defined as =24 hours of acute care.	Baseline through Days 29, 60, and 90
Secondary	Percentage of Participants With a COVID-19-related Hospitalization	Hospitalization is defined as =24 hours of acute care.	Baseline through Days 29, 60, and 90
Secondary	Percentage of Participants With a COVID-related Emergency Department (ED) Visit	Percentage of Participants with a COVID-related ED Visit.	Baseline through Days 29, 60, and 90

External Links

•   A Real World Study of Bamlanivimab in Participants With Mild-to-moderate Coronavirus Disease 2019 (COVID-19) (BLAZE-5)